Comparison of positron emission tomography, cognition, and brain volume in Alzheimer’s disease with and without severe abnormalities of white matter

C DeCarli, C L Grady, C M Clark, D A Katz, D R Brady, D G M Murphy, J V Haxby, J A Salerno, J A Gillette, A Gonzalez-Aviles, S I Rapoport

Abstract

Objectives—To examine cerebral metabolism, cognitive performance, and brain volumes in healthy controls and two groups of patients with probable Alzheimer’s disease, one group with severe abnormalities of white matter (DAT+) and the other group with none, or minimal abnormalities (DAT−).

Methods—Neuropsychological tests, CT, MRI, quantitative MRI, and PET studies were carried out to allow comparison between the DAT+ and DAT− groups and the healthy controls.

Results—Compared with the healthy controls, both demented groups had significantly reduced global and regional cerebral metabolism, significant brain atrophy, and significantly lower scores on neuropsychological testing.

The DAT− patient group showed a pattern of parietal-temporal cerebral metabolic reductions and neuropsychological performance deficits typical of Alzheimer’s disease. In addition, metabolism in the association neocortex (AD ratio) and measures of neuropsychological task performance were significantly correlated in the DAT− patient group.

Comparison of DAT+ with DAT− patients showed significantly higher ratio of parietal to whole brain glucose utilisation for the DAT+ group. Moreover, when comparing group Z score differences from the healthy controls, the DAT+ group had, on average, smaller differences from controls in the frontal, parietal, and temporal regions than did the DAT− group. Discriminant analysis using metabolic ratios of the frontal, parietal, and temporal regions showed cerebral metabolic patterns to be significantly different among the DAT+, the DAT−, and the healthy controls. These differences were due primarily to relatively higher frontal, parietal, and temporal metabolic ratios in the DAT+ group which resulted in discriminant scores for the DAT+ group between the healthy controls and the DAT− group.

Group mean scores on tests of neuropsychological performance were not significantly different between the DAT− and DAT+ patients. By contrast with the DAT− group, however, no significant correlations between the AD ratio and any neuropsychological task were seen in the DAT+ group. Multiple regression analysis showed significant between group differences in the relation between the AD ratio and neuropsychological scores on three tasks. The slopes of the relations between the AD ratio and memory scores (memory and freedom from distractibility deviation quotient of the Wechsler adult intelligence scale (WMDQ)) also were significantly different for the two groups.

Conclusions—Although multiple causes for abnormalities of white matter exist in patients with Alzheimer’s disease, these data suggest that the presence of severe abnormalities of white matter indicate a second pathologic process in the DAT+ patients. The DAT+ patients showed the parietal-temporal metabolic deficits and correlations between association neocortical metabolism and neuropsychological task performance typical of patients with Alzheimer’s disease. By contrast, the DAT+ group had a pattern of cerebral metabolism significantly different from healthy controls and DAT+ patients, as well as no significant correlations between metabolism in the association neocortex and neuropsychological performance. These differences probably reflect the superimposed pathology of the abnormalities of white matter which may exert their affect through disruption of long corticocortical pathways.

Keywords: dementia of the Alzheimer type; leukoaraiosis; magnetic resonance imaging; positron emission tomography

Abnormalities of cerebral white matter occur as part of normal aging, and are more prevalent in people with hypertension and cerebrovascular disease. Our understanding of how abnormalities of white matter affect cerebral structure and function, however, remains uncertain. In non-demented elderly subjects, most recent studies concur with the idea that abnormal white matter signals are associated with poorer neuropsychological test performance, brain atrophy, reduced cerebral blood flow and glucose utilisation, focal neurological signs, and a gait disorder. Examination of the same relations in patients with probable Alzheimer’s disease has proved...
Comparison of positron emission tomography, cognition and brain volume in Alzheimer’s disease with and without severe abnormalities of white matter

Methods

SUBJECTS

Healthy controls

The healthy control subjects consisted of seven men and seven women. Each subject underwent rigorous medical, neurological, and laboratory screening. Subjects with medical illness, psychiatric disorders, history of head trauma, or substance misuse were excluded. No subject received medication in the two weeks before the evaluation.

DAT− patients

The DAT− patient group consisted of eight men and six women selected with the same stringent health screening criteria as the healthy controls. For each patient, Alzheimer’s disease was diagnosed as “probable” using NINCDS-ADRDA criteria. The degree of cognitive impairment was graded according to mini mental state examination (MMSE) scores as mild (MMSE > 20), moderate (> 10 MMSE < 20), and severe (MMSE < 10). The DAT− patients were chosen from a larger group and were selected to be comparable with the DAT+ group for age, education, severity of dementia, and duration of illness.

Five DAT− patients subsequently died. All met pathological criteria for definite Alzheimer’s disease.

DAT+ patients

The DAT+ patient group consisted of six men and six women identified consecutively with severe abnormalities of white matter on brain imaging, and who otherwise met clinical criteria for probable Alzheimer’s disease. Health screening differed from the healthy controls and DAT− patients in that seven of 12 had hypertension. Patients with stroke, either by history or on structural imaging were excluded. Alzheimer’s disease was diagnosed in the same fashion as the DAT− group.

Five DAT+ patients subsequently died. All met pathological criteria for definite Alzheimer’s disease.

STUDY DESIGN

All patients and controls participated as part of three separate, but concurrent, longitudinal studies at the Laboratory of Neurosciences, National Institute on Aging (NIA), National Institutes of Health. All patients and controls signed informed consent forms developed in accordance with NIH guidelines, and reviewed by the NIA Internal Review Board. For the demented patients, these studies required a brief inpatient stay, off all medications, during which time careful clinical evaluation, extensive neuropsychological testing, structural brain imaging (MRI and CT), and PET were obtained.

RATING OF ABNORMALITIES OF WHITE MATTER ON BRAIN IMAGES

The presence of abnormalities of white matter was determined from either non-contrast CT, T2 weighted MRI, or both. Leukoaraiosis on non-contrast head CT was identified as present or absent by radiologists unaware of the clinical status of the subject and using the definition of Hachinski et al.

Leukoaraiosis of moderate to severe degree was present on CT
of each DAT+ patient, but was absent from the CT of the DAT- patients and healthy controls. In addition, an MRI spin echo brain image was obtained for most of the demented patients and all healthy controls. We used the four point scale of Fazekas et al.\(^7\) for rating white matter hyperintensities (0 = absent; 3 = severe). Qualitative ratings of the healthy controls and DAT− patients did not exceed a rating of 1 for periventricular or deep white matter hyperintensities on T2 weighted images (TR 2000, TE 80). The DAT+ patients, however, had ratings of at least 3 for periventricular or deep white matter hyperintensities. Figure 1 is an example of the group differences in structural images between the DAT− and DAT+ patients.

NEUROPSYCHOLOGY

The Wechsler adult intelligence scale (WAIS\(^{39}\)), Benton facial recognition test\(^{40}\), Boston naming test\(^{40}\), and the extended range drawing test\(^{41}\) were given to evaluate general intellectual, verbal, and visuospatial functions. Tests of immediate and delayed recall for stories and figures from the Wechsler memory scale were used as standard measures of visual and verbal memory.\(^42\) Frontal lobe executive function, thought to be preferentially affected by abnormalities of cerebral white matter,\(^{43,44}\) was measured with the Porteus maze;\(^44\) Stroop colour-word interference task, and trails part A and part B.\(^{45,46}\) Neuropsychological testing was attempted for all the patients with dementia, but one DAT+ and one DAT− patient were unable to fully cooperate.

QUANTITATIVE MRI

Brain MRI was performed on a 0.5 Tesla scanner (Picker Instruments, Cleveland, OH). Axial images were analysed using the proton density (TR 2000, TE 20) portion of a double echo sequence (TR 2000/20/80) according to previously published methods.\(^47,48\) Eighteen 7 mm thick contiguous slices were obtained from the foramen magnum to the vertex, parallel to an estimated orbitomeatal line. A region of interest analysis\(^46\) was applied to determine the volumes of the cerebral ventricles, and segmentation analysis\(^47\) to determine cerebral and hemispheric CSF and brain volumes. To correct for individual differences in head size on measures of brain volume,\(^49\) all statistical comparisons were performed on brain and CSF volumes calculated as a percentage of total intracranial volume. Five of the 25 demented patients were unable to cooperate enough to obtain MRIs of sufficient quality for quantification. These patients were more severely demented, and had a mean MMSE score of 7-3 (SD 8-5).

PET STUDIES

Brain PET was performed on a Scanditronix PC1024–7B tomograph (Uppsala, Sweden), a seven slice machine with a transverse resolu-
Comparison of positron emission tomography, cognition and brain volume in Alzheimer's disease with and without severe abnormalities of white matter

Table 1  Comparison of demographic variables for DAT−, DAT+ patients and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>DAT−</th>
<th>DAT+</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>14</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>8/6</td>
<td>6/6</td>
<td>7/7</td>
</tr>
<tr>
<td>Age (y)</td>
<td>71±6 (8-0)</td>
<td>75±4 (6-0)</td>
<td>65±4 (7-0)*</td>
</tr>
<tr>
<td>(61-86)</td>
<td>(66-83)</td>
<td>(58-81)</td>
<td></td>
</tr>
<tr>
<td>Education (y)</td>
<td>15±3 (2-7)</td>
<td>13±3 (4-4)</td>
<td>15±2 (2-2)</td>
</tr>
<tr>
<td>Duration of dementia (y)</td>
<td>11±19</td>
<td>5±5 (2-3)</td>
<td>(2-14)</td>
</tr>
<tr>
<td>MMSE</td>
<td>12±8 (8-1)</td>
<td>12±0 (9-9)</td>
<td>29±6 (1-0)*</td>
</tr>
<tr>
<td>Ischaemic scale</td>
<td>1-0 (1-4)</td>
<td>2-9 (1-6)</td>
<td>(0-6-2)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0/14</td>
<td>7/12</td>
<td>0/14</td>
</tr>
</tbody>
</table>

Values are mean (SD) and (range) beneath.
*DAT− and DAT+ are significantly different from healthy controls.
†DAT+ is significantly different from DAT−.
‡DAT+ is significantly different from controls and DAT−.
§From Hachinski et al.15

PET DATA ANALYSIS

Data from PET were analysed with a template of circular regions of interest 8 mm in diameter (48 mm²). The regions of interest were spaced evenly throughout the cortical and subcortical regions. Regional metabolic rates were obtained by averaging values in the circular regions that fell within anatomically recognised areas, such as the superior parietal or superior temporal areas.22 Both absolute regional cerebral metabolic rates for glucose (rCMRglc) and ratio measures of rCMRglc to whole brain metabolic rates for glucose (rCMRglc/CMRglc) were used for group comparisons.

We also calculated a metabolic ratio (AD ratio) in which the numerator was the average of the association neocortical regions (frontal, temporal, and parietal) and the denominator was the average of primary sensory and motor, basal ganglia, and cerebellar regions. Previous studies33 have shown that this ratio is highly correlated with the cognitive deficits of patients with Alzheimer's disease.

STATISTICAL ANALYSES

Group differences in dichotomous variables were analysed using a χ² test after continuity adjustment or Fisher's exact test.44 Age, education, duration of illness, neuropsychological test scores, and quantitative MRI volumes were compared between the DAT− and DAT+ groups with Student's t test. The relations between quantitative MRI and PET measures and neuropsychological performance scores were tested with Pearson correlations. Further examination of the relation between the AD ratio and neuropsychological test scores was performed with multiple regression analysis.45 Between group differences in rCMRglc were compared by three way analysis of variance (ANOVA) with post hoc mean comparisons.44 Patterns of cerebral metabolism were compared between the healthy controls, DAT+, and DAT− groups by discriminant analysis. Discriminant function scores were also compared with three way ANOVA and post hoc mean comparison.

Results

DEMOGRAPHICS

Table 1 summarises the group demographics. The healthy controls were significantly younger than the dementia groups. The dementia groups did not differ significantly on age, duration of illness, years of education, or mean MMSE. The DAT+ group had a significantly higher prevalence of hypertension (χ² = 9.8, P < 0.002), and significantly higher ischaemic scale scores (P < 0.05).

PET STUDIES

The rCMRglc and CMRglc values were significantly greater in the healthy controls compared with the demented patients for all brain regions except the cerebellum and cerebral white matter. No significant differences in rCMRglc between the DAT− and DAT+ patients were found (data not shown). When cerebral metabolism was assessed as the ratio to whole brain metabolism (rCMRglc/CMRglc), as summarised in table 2 however, DAT+ patients had significantly greater parietal ratios than the DAT− patients.

To further examine regional metabolic differences between the DAT+ and DAT− groups, regional cerebral metabolism was converted into z score differences from healthy controls. To calculate each z score, the healthy control group mean rCMRglc was subtracted from each patient's rCMRglc and divided by the healthy control group rCMRglc SD. Figure 2 shows the mean z score differences from controls in rCMRglc/CMRglc. The DAT− group shows the typical frontal, tem-

Table 2  Regional comparison of rCMRglc/CMRglc for controls, DAT−, and DAT+ patients

<table>
<thead>
<tr>
<th>Region</th>
<th>Controls</th>
<th>DAT−</th>
<th>DAT+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole brain</td>
<td>6.27 (1.13)*</td>
<td>4.56 (1.01)*</td>
<td>4.32 (0.87)*</td>
</tr>
<tr>
<td>Frontal lobe</td>
<td>1.30 (0.05)</td>
<td>1.27 (0.11)</td>
<td>1.28 (0.21)</td>
</tr>
<tr>
<td>Parietal lobe</td>
<td>1.34 (0.06)*</td>
<td>1.14 (0.11)*</td>
<td>1.24 (0.15)*</td>
</tr>
<tr>
<td>Temporal lobe</td>
<td>1.51 (0.06)</td>
<td>1.07 (0.15)</td>
<td>1.12 (0.11)</td>
</tr>
<tr>
<td>Sensory motor cortex</td>
<td>1.33 (0.05)*</td>
<td>1.44 (0.16)</td>
<td>1.56 (0.19)*</td>
</tr>
<tr>
<td>Calcarine cortex</td>
<td>1.32 (0.07)*</td>
<td>1.50 (0.19)</td>
<td>1.52 (0.27)*</td>
</tr>
<tr>
<td>Basal ganglia</td>
<td>1.49 (0.13)</td>
<td>1.71 (0.25)</td>
<td>1.66 (0.16)*</td>
</tr>
<tr>
<td>White matter</td>
<td>0.49 (0.14)</td>
<td>0.62 (0.19)</td>
<td>0.54 (0.12)</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>1.12 (0.10)*</td>
<td>1.38 (0.21)</td>
<td>1.44 (0.19)*</td>
</tr>
<tr>
<td>Brain stem</td>
<td>0.98 (0.15)*</td>
<td>1.14 (0.21)</td>
<td>1.13 (0.19)*</td>
</tr>
</tbody>
</table>

Values are mean (SD); values with different superscripts are significantly different from each other after correcting for multiple comparisons.
Figure 2 Regional group mean z score differences from healthy controls across 32 sampled regions. See text for explanation of regions of interest. The black horizontal lines indicate z scores of 2 and –2. PREF = prefrontal cortex; PREM = premotor cortex; SUPPAR = superior parietal cortex; IPAR = inferior parietal cortex; MIDTMP = middle and inferior temporal cortices; SUPTMP = superior temporal cortex; AM TMP = amygdala; anterior medial hippocampal and parahippocampal cortices; ORBFR = orbital frontal cortex; ANCIN = anterior cingulate; OCA = Brodmann area 18 and 19; CALC = calcarine cortex; SM = precenrtal and postcentral gyri; LENT = lenticular nucleus; CAUD = caudate; THAL = thalamus. L = left, R = right.

Temporal, parietal pattern of hypometabolism thought to be characteristic of Alzheimer’s disease, whereas the DAT+ group shows a relative sparing of metabolism in these areas.

Given these between group differences, discriminant analysis was performed using the frontal, parietal, and temporal metabolic ratios (listed as R PREF to LSUPTMP in fig 2). We chose discriminant analysis as this statistical method allows for estimation of the linear combination of all the regions on group differences. We also included the healthy control group in this analysis to show how the two dementia groups differ, not only from each other, but in relation to subjects without dementia (are the two dementia groups different because one group looks more like the healthy controls, or is the pattern of cerebral metabolism uniquely different among each of the dementia groups and controls?). Because the discriminant analysis was performed between three groups, two discriminant functions are generated and subject classification is based on a weighted combination of the scores along each function. Subject classification based on the combined information of the two discriminant functions was significant (Wilks’ lambda = 0.24, F 25,19 = 2.06, P = 0.017) and completely accurate for all groups. That is, each subject used to derive the discriminant function was correctly classified as DAT+, DAT−, or healthy control.

The first discriminant function explained 81% of the between group differences (P < 0.02). Individual discriminant scores correlated significantly (P < 0.01) with the right and left frontal premotor, right and left superior and inferior parietal, and right and left middle temporal metabolic ratios, regions preferentially involved in Alzheimer’s disease.111 The group discriminant score means were 1.57 (SD 0.85) for the healthy controls, –0.17 (SD 0.97) for the DAT+ patients, and –1.55 (1.55) for the DAT− patients. Analysis of variance showed a significant group effect of discriminant scores (F1,25 = 33, P < 0.0001). On post hoc analysis, each group was significantly different from the others. The DAT+ patients, therefore, had a significantly different pattern of glucose utilisation with generally higher metabolic ratios than the DAT− patients, but generally lower metabolic ratios than the healthy controls.

The second discriminant function explained the remaining variance, but was not significant (F1,32 = 0.98, P = 0.49). The group discriminant score means along this function, however, were 0.34 (SD 0.86) for the healthy controls, 0.46 (SD 1.17) for the DAT−

DeCarli, Grady, Clark, Katz, Brady, Murphy, et al
parietal region 11%, and the left middle temporal region explained the remaining error. The regions found by the stepwise discriminant function also significantly discriminated between groups (P < 0.05), and similarly to the previous discriminant function, the mean discriminant scores were negative for the DAT− group, near zero for the DAT+ group, and positive for the healthy controls.

**NEUROPSYCHOLOGY**
The two dementia groups performed worse (P < 0.001) than the healthy controls on each of the neuropsychological tests. The DAT+ patients performed worse, on average, than the DAT− patients, but this difference was significant only for Benton facial recognition test scores (table 3).

Patterns of cerebral metabolism have been associated with patterns of cognitive performance in patients with Alzheimer's disease. If abnormalities of white matter alter cerebral metabolism and cognitive performance in healthy subjects, we would expect their presence to have a similar effect in the DAT+ patients. Using the metabolic ratio (AD ratio) described by Mielke et al., we examined the relation between cerebral glucose metabolism and severity of dementia for the DAT− and DAT+ groups. The mean AD ratio scores were 0.83 (SD 0.13) for the DAT− group and 0.86 (SD 0.10) for the DAT+ group. Table 4 shows the zero order correlations between the AD ratio and various scales of the WAIS and the MMSE.

Significant and large correlations between the AD ratio and four of the scale scores of the WAIS and the MMSE were found for the DAT− patients, whereas no relation was significant for the DAT+ patients. As small group size and high variance could have contributed to the lack of significant correlations between the AD ratio and neuropsychological test scores in the DAT+ group, we performed a multiregression analysis of the relation between the neuropsychological test scores and AD ratio to assess whether this relation was the same for the two demented groups. All multiple regression models were statistically significant (P < 0.05). In three models where MMSE, WAIS verbal deviation quotient (WVDQ), and WAIS memory and freedom from distractability deviation quotient (WMDQ) were used to predict the AD ratio, the group effect was significant. In three other models where WAIS full scale IQ (WFSIQ), WAIS verbal IQ (WVIQ), and WAIS perfor-

![Figure 3](image)

**Figure 3** Relation between discriminant scores on the first and second discriminant functions for each group.

<table>
<thead>
<tr>
<th>Table 3 Neuropsychological scores DAT− v DAT+ patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neuropsychological task</strong></td>
</tr>
<tr>
<td>-------------------------------</td>
</tr>
<tr>
<td>Full scale IQ</td>
</tr>
<tr>
<td>Verbal IQ</td>
</tr>
<tr>
<td>Performance IQ</td>
</tr>
<tr>
<td>Wechsler immediate verbal memory</td>
</tr>
<tr>
<td>Wechsler delayed verbal memory</td>
</tr>
<tr>
<td>Wechsler immediate visual memory</td>
</tr>
<tr>
<td>Wechsler delayed visual memory</td>
</tr>
<tr>
<td>Extended range drawing</td>
</tr>
<tr>
<td>Benton facial recognition</td>
</tr>
<tr>
<td>Boston naming</td>
</tr>
<tr>
<td>Porteus maze</td>
</tr>
<tr>
<td>Stroop interference</td>
</tr>
<tr>
<td>Trails A</td>
</tr>
<tr>
<td>Trails B</td>
</tr>
</tbody>
</table>

Values are mean (SD); the dementia group means for each neuropsychological test differed significantly from healthy controls.

*DAT+ differs from DAT− (P < 0.05).*

patients, and −0.98 (SD 0.95) for the DAT+ patients.

Examination of the biterриториal map of standard scores on the first and second discriminant functions (fig 3) disclosed three distinct clusters consistent with a unique metabolic pattern for each group. The healthy controls clustered in the positive range of the first function, but near zero in the second function. The DAT− group clustered in the negative range on the first function and along the entire axis on the second function. The DAT+ group, however, clustered near zero on the first function but negatively on the second function in the area not occupied by either the controls or DAT− groups.

Because the discriminant analysis was performed on many regions, we also examined which regions had the greatest independent effect on the group differences by using stepwise discrimination. Nearly all the between group differences were explained by four variables. The left inferior parietal region explained 20% of the variance, the right frontal premotor region 30%, the left superior

![Table 4](image)

**Table 4** Correlation of neuropsychological scores with AD ratio for DAT− v DAT+ patients

<table>
<thead>
<tr>
<th>Neuropsychological test</th>
<th>WFSIQ</th>
<th>WVIQ</th>
<th>WVIQ</th>
<th>WVDQ</th>
<th>WMDQ</th>
<th>WPDQ</th>
<th>MMSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correlations:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAT−</td>
<td>0.64*</td>
<td>0.60*</td>
<td>0.61</td>
<td>0.57</td>
<td>0.58*</td>
<td>0.41</td>
<td>0.66*</td>
</tr>
<tr>
<td>DAT+</td>
<td>0.46</td>
<td>0.40</td>
<td>0.55</td>
<td>0.37</td>
<td>0.32</td>
<td>0.39</td>
<td>0.46</td>
</tr>
<tr>
<td>Test for difference of slopes AD ratio = test group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F&lt;sub&gt;13,12&lt;/sub&gt;</td>
<td>2.1</td>
<td>2.77</td>
<td>0.01</td>
<td>3.49</td>
<td>5.20</td>
<td>1.13</td>
<td>2.84</td>
</tr>
<tr>
<td>P value</td>
<td>0.16</td>
<td>0.11</td>
<td>0.92</td>
<td>0.08</td>
<td>0.03</td>
<td>0.30</td>
<td>0.11</td>
</tr>
</tbody>
</table>

*Significant correlation.
For abbreviations see text.
mance deviation quotient (WPDQ) were used to predict the AD ratio, the group effect showed a trend toward significance with P values ≤ 0.10. Moreover, in the model, when WMDQ was used to predict the AD ratio, the interaction term between group and WMDQ was significant, and in three other models, where WVDQ, WVIQ, and MMSE were used as predictors the interaction term had a P value ≤ 0.11. Figure 4 shows the relation between AD ratios and WMDQ scores. The AD ratio was greater for the DAT+ group (significant group effect, F(1,24) = 7.4, P < 0.05), and the slopes of group regression lines were significantly different (significant interaction, F(1,24) = 5.2, P < 0.05), indicating a different relation between the AD ratio and WMDQ scores.

Age, years of education, and sex are also known to influence performance on neuropsychological tasks in healthy subjects. As between group differences on these variables could have influenced analysis of neuropsychological test scores between the DAT+ and DAT− groups, we examined the predictive value of these variables on each neuropsychological task. None significantly predicted performance on any neuropsychological task.

**Discussion**

Our results show that the presence of severe abnormalities of white matter in DAT+ patients significantly affected the pattern of resting cerebral glucose metabolism and significantly altered the relation between regional cerebral metabolism and WMDQ scores. Whereas DAT+ patients scored lower than DAT− on neuropsychological tests, these differences were generally non-significant. Brain volumes were nearly identical for the two groups.

The findings of an altered pattern of cerebral metabolism and a significantly different relation between cerebral metabolism and WMDQ scores supports the notion that abnormalities of white matter in patients with DAT+ reflect a pathophysiological process that is different from Alzheimer’s disease. Most of our DAT+ patients had hypertension, however. As hypertension is associated with brain atrophy and a higher prevalence of abnormalities of white matter, it is possible that the differences in cerebral metabolism and the differences in the relation between cerebral metabolism and WMDQ scores could simply reflect the effect of hypertension on the brains of DAT+ patients. Non-hypertensive patients without severe white matter changes have reduced cerebral metabolism compared with controls, but without significant reductions in neuropsychological performance. The degree of reduced glucose utilisation is small, however, and maximal in the vascular watershed brain regions, a distribution different from the metabolic pattern of Alzheimer’s disease. So, although hypertension may be causal to the abnormalities of white matter in the DAT+ patients, it does not seem that the metabolic differences can be explained by the hypertension alone.

With regard to group mean differences in neuropsychological performance, our results are consistent with some, but not all, reports of neuropsychological testing in dementia with abnormalities of white matter. Our patients differ from previously reported patient groups in that we selected two groups for which abnormalities of white matter were either minimal or very severe. In addition, the patients were moderately to severely demented.

Although we sought to select patients with maximal differences in abnormalities of white matter in the hope of finding clinical charac-
Comparison of positron emission tomography, cognition and brain volume in Alzheimer's disease with and without severe abnormalities of white matter

Characteristics specific to these abnormalities, it could be that subtle neuropsychological differences are present when the dementia is mild, but are overwhelmed by the Alzheimer's disease process. Significant group differences in neuropsychological scores related to the presence of abnormalities of white matter, therefore, may not have been seen due to the moderate to severe degree of cognitive impairment in our patients. Small group size could have also limited our results. Consistent with previous data, the DAT+ patients had generally lower neuropsychological test scores than the DAT- patients. Larger sample sizes would have given us the statistical power necessary to more accurately ascertain whether these differences were truly significant under the conditions tested.

We were, however, most interested in the relation between neuropsychological performance and cerebral metabolism among the DAT- and DAT+ groups. The pattern of neocortical glucose metabolism was significantly different between the two dementia groups; however, as noted, both groups had a generally equal degree of dementia severity. This suggests that dysfunction of different brain regions may underlie the cognitive deficits among the two groups. Previous reports have shown significant relations between cerebral metabolism in the association neocortices and numerous neuropsychological tasks in patients with Alzheimer's disease. Using the AD ratio reported by Mielke et al., we duplicated the previously reported significant correlation between neuropsychological performance and metabolism for the DAT- group, but not the DAT+ group. Multivariate analyses of the relation between the AD ratio and neuropsychological test scores for the two dementia groups also showed significant group differences on one neuropsychological task, and a trend toward significance for three others which was not explained by the confounding effects of age, sex, and education. Although the interaction was significant only on one neuropsychological measure, this particular task reflects memory and attentional processes which have been previously shown to be affected in healthy subjects with abnormalities of white matter. Given the trend toward significance in three additional cognitive tasks, larger patient groups might have disclosed more generalised differences in the relation between neocortical metabolism and neuropsychological tests.

Wallerian degeneration of cortical neurons caused by Alzheimer's disease has been one hypothesis proposed to explain the increased prevalence of abnormalities of white matter in patients with Alzheimer's disease. If neuronal cell death and subsequent Wallerian degeneration of axons was the sole cause of abnormalities of white matter in Alzheimer's disease, we would expect to see greater cerebral atrophy in the DAT+ group when compared by dementia severity. Or, if not mean differences in cerebral volume, differences in the relation between severity of dementia and cerebral volume in patients with DAT+. We found neither. Not only were the group mean volumes nearly identical, but the relation between cerebral volume and dementia severity was the same for both groups. Non-demented subjects with abnormalities of white matter have significantly greater cerebral atrophy, however, suggesting that these abnormalities are associated with tissue loss. The volume of tissue loss associated with abnormalities of white matter, although significant, is relatively small (about 3-0% in one study). Tissue loss caused by Alzheimer's disease is greater than the tissue loss due to abnormalities of white matter, and may therefore obscure group differences in brain volume caused by abnormalities of white matter in the DAT+ group.

Our data, however, do mitigate against the notion that abnormalities of white matter are the inevitable consequence of Alzheimer's disease. Members of both the DAT+ and DAT- groups spanned the entire range of severity of dementia, including patients with minimal to severe cerebral atrophy. In addition, five members of each dementia group have had pathological confirmation of Alzheimer's disease. Detailed analysis of cerebral vasculature, white matter, and grey matter in a subset of these patients showed the presence of severe cerebral amyloid angiopathy, myelin pallor, and astrocytosis without axon loss in the DAT+ group, which was absent from the DAT- patients. These data suggest that a pathology additional to, or coincident with, the markers of Alzheimer's disease, such as cerebral amyloid angiopathy, or other processes known to cause abnormalities of white matter, such as hypertensive vasculopathy, are present in patients with Alzheimer's disease with severe abnormalities of white matter.

How abnormalities of white matter might affect cerebral metabolism and cognition was not considered in our study. One hypothesis proposes that abnormalities of white matter affect cerebral metabolism through impairment of long corticocortical neurons leading to a functional “disconnection”. Healthy subjects with large hypertensive lesions in white matter show significant reductions in frontal lobe glucose utilisation which has been attributed to damage to corticocortical axons passing through central cerebral white matter. A similar process could explain the metabolic pattern of the DAT+ patients, in whom the prototypical temporal-parietal dysfunction of Alzheimer's disease is diminished, and a more generalised reduction of cerebral metabolism is seen instead. Dysfunction in brain regions outside the temporal and the parietal lobes, particularly in the frontal lobe, might contribute to the cognitive impairment seen in the DAT+ patient group, and is consistent with the clinical findings of less pronounced parietal lobe dysfunction in patients with Alzheimer's disease with abnormalities of white matter.

Although the aetiology may be diverse (for example, aging, cerebral amyloid angiopathy,
or hypertension), the presence of severe abnormalities of white matter in patients with dementia affects the pattern of cerebral metabolism of glucose and the relation between Alzheimer's disease rate and WMDQ scores. In this regard, DAT+ patients seem to be a subgroup of Alzheimer's disease wherein abnormalities of white matter indicate another concurrent pathological process. The clinical and research implications are unclear at this time, but further studies might elucidate these differences.

We thank Dr Vladimir Hachinski, Dr Bruce Miller, and Dr John Bowler for their helpful comments.

30Folstein ME, Folstein SE, MacHugh P. “Mini-state- \n
35Folstein ME, Folstein SE, MacHugh P “Mini-state- \n
Baron Constantin von Economo and encephalitis lethargica

Although younger neurologists may not have encountered postencephalitic parkinsonism, encephalitis lethargica merits mention in contemporary reviews of Parkinson's disease. The name of von Economo is inseparably and justifiably attached to the disease since he was the major describer of an illness that raged in epidemic form in Europe and North America between 1916 and 1926. Ivy McKenzie provided a scholarly account of the illness in Glasgow.1 Longer texts were written by Jelliffe,2 and by Wimmer.3 At first, others confused encephalitis lethargica with the pandemic of influenza (Spanish grippe). Cruccher had first noted encephalitis lethargica in the winter of 1915–16 in French soldiers in Verdun,4 and a few cases were seen in the spring of 1915 in Rumania.

von Economo published 27 papers including a book5 on encephalitis lethargica.

Excerpts from a translation of his classic description

"We are dealing with a kind of sleeping sickness, having an unusually prolonged course. The first symptoms are usually acute, with headaches and malaise. Then a state of somnolence appears, often associated with active delirium from which the patient can be awakened easily. He is able to give appropriate answers, and to comprehend the situation. This delirious somnolence can lead to death, rapidly, or over the course of a few weeks. On the other hand it can persist unchanged for weeks or even months with periods lasting hours or days or even longer, of fluctuation of the depth of unconsciousness extending from simple sleepiness to deepest stupor or coma. . . During the first days of the illness, isolated signs of meningeal irritation appear. . . The appearance of fever and its intensity do not seem to have any effect upon the course and signs of the disease . . .

As a rule these general symptoms are joined by paralysis of the cranial nerves as well as in the extremities . . . a paralytic ptosis often combined with partial or total paralysis of other branches of the oculomotor nerve . . . Paresis of the other cranial nerves and paralysis of the extremities with reflex disturbances can occur also" [seven case reports and an account of the clinical features are then given] . . .

"The spinal fluid . . . showed increased pressure at the beginning; it later decreased in spite of persistent somnolence. The total protein was below the normal upper limit; . . . In case 1, 43 cells/mm³, in case 2, 19 cells/mm³ . . . strong predominance of polymorphonuclear leukocytes. Repeated examination of the spinal fluid contribute to "leuko-araiosis" in subjects free of any antecedent diseases. J Neurol Neurosurg Psychiatry 1988;51:46–50.


